KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Average (2016 - 2025)

Historic Equity Average for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $7.6 billion.

  • Teva Pharmaceutical Industries' Equity Average rose 2894.67% to $7.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 billion, marking a year-over-year increase of 2894.67%. This contributed to the annual value of $6.6 billion for FY2025, which is 156.97% down from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Equity Average is $7.6 billion, which was up 2894.67% from $7.0 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Equity Average high stood at $11.4 billion for Q3 2021, and its period low was $5.8 billion during Q1 2025.
  • Its 5-year average for Equity Average is $8.5 billion, with a median of $7.9 billion in 2023.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Equity Average tumbled by 2568.21% in 2021, and later soared by 2894.67% in 2025.
  • Teva Pharmaceutical Industries' Equity Average (Quarter) stood at $11.3 billion in 2021, then fell by 20.23% to $9.1 billion in 2022, then dropped by 14.31% to $7.8 billion in 2023, then fell by 24.17% to $5.9 billion in 2024, then rose by 28.95% to $7.6 billion in 2025.
  • Its Equity Average stands at $7.6 billion for Q4 2025, versus $7.0 billion for Q3 2025 and $6.6 billion for Q2 2025.